AOD-9604 MMA / Combat Sports Protocol: Dosing, Timing, and Evidence

What Is AOD-9604 and Why Do Combat Athletes Use It?

AOD-9604 is a 16-amino-acid C-terminal fragment of human growth hormone, corresponding to positions 176-191 of the hGH sequence. Unlike full-length hGH, it does not bind the primary GH receptor in a way that raises IGF-1 to supraphysiologic levels, which is why early researchers hoped it could deliver fat-burning effects without the glucose dysregulation or tissue growth associated with exogenous hGH [1].

Combat sports athletes, particularly those competing in weight-class sports such as MMA, boxing, and wrestling, face a specific set of physiological stressors: repeated subconcussive and concussive impacts, high-load grappling that strains ligaments and fibrocartilage, aggressive weight cuts, and compressed recovery windows between fights. AOD-9604 has entered combat-sports peptide stacks because practitioners report it may support fat loss during caloric restriction without the anabolic side-effect profile of hGH, and because animal cartilage-repair data have been extrapolated, cautiously, to soft-tissue recovery [2].

The hGH Fragment Mechanism

Full-length hGH drives lipolysis through a region near the C-terminus. AOD-9604 isolates that region. In vitro and rodent studies from the Monash University group showed the fragment stimulates lipolysis in isolated adipocytes and reduces fat mass in obese mice without producing hyperglycemia or IGF-1 elevation [1]. A 2001 paper in the American Journal of Physiology confirmed that the fragment retains roughly the same lipolytic potency as full hGH in isolated rat adipocytes [3].

Why IGF-1 Neutrality Matters for Athletes

Exogenous hGH raises serum IGF-1, which is detectable on WADA-accredited anti-doping tests and is prohibited under WADA S2. AOD-9604, at doses used in clinical trials (up to 1 mg/day oral), did not raise IGF-1 above baseline in human subjects [4]. That profile is one reason MMA strength-and-conditioning coaches began including it in off-season peptide stacks, though athletes must understand that regulatory language around peptide hormones is broad and evolving.

Clinical Evidence: What the Human Data Actually Show

Most of the human evidence for AOD-9604 comes from a Phase II/III program sponsored by Metabolic Pharmaceuticals (Australia) between 2001 and 2004. The program tested an oral formulation, not the subcutaneous injection form used by most athletes today. Understanding that distinction is clinically important.

Phase II Weight-Loss Trials

A 12-week, double-blind, placebo-controlled trial (N=300) tested oral AOD-9604 at doses of 1 mg and 2 mg daily in overweight adults. The 1 mg group lost a mean of 2.6 kg versus 0.8 kg in placebo (P<0.05). The 2 mg group showed no additional benefit, suggesting a dose ceiling [4]. Fasting glucose, insulin, and IGF-1 remained unchanged from baseline across all active arms, supporting the early mechanistic claim that the fragment does not activate the full GH receptor pathway [4].

Cartilage and Soft-Tissue Data

No peer-reviewed RCT in humans has evaluated AOD-9604 for cartilage repair, ligament healing, or concussion recovery. The preclinical data that underpin practitioner interest come from two sources.

First, a 2014 study published in Growth Factors (Taylor & Francis) showed intra-articular AOD-9604 reduced histological cartilage damage scores in an ovine model of osteoarthritis compared to saline control over 13 weeks [2]. Second, a separate in vitro experiment demonstrated that AOD-9604 may stimulate chondrogenic differentiation of adipose-derived stem cells, though the concentration used (100 ng/mL) is difficult to translate into a systemic subcutaneous dose in a human athlete [5].

These are Level IV-V data by the Oxford Centre for Evidence-Based Medicine hierarchy [6]. Practitioners who cite them as justification for subcutaneous AOD-9604 post-injury are making an extrapolation that has not been validated in a human clinical trial.

Oral vs. Subcutaneous Bioavailability

The Phase II trials used an oral formulation developed specifically for gastrointestinal stability. Subcutaneous injection bypasses first-pass metabolism and is assumed by practitioners to achieve higher systemic exposure, but no published pharmacokinetic study directly compares oral to subcutaneous AOD-9604 bioavailability in humans [7]. This is a genuine evidence gap that athletes and clinicians should acknowledge before designing a protocol.

Structured Protocol for MMA and Combat Sports

The following protocol is a synthesis of published Phase II dosing data, preclinical tissue-repair findings, and practitioner-reported experience documented in peer-reviewed peptide pharmacology reviews. Where evidence grade drops below Level II, the section is labeled accordingly.

Phase 1: Body Composition / Weight-Cut Support (Weeks 1-8)

Goal: Reduce fat mass while preserving lean tissue during caloric restriction in the lead-up to a fight camp.

Dose: 300 mcg subcutaneous injection, once daily, administered in a fasted state (minimum 2 hours post-meal, 30 minutes pre-meal). Morning administration or 30-60 minutes before sleep are both used in practice; no head-to-head human comparison exists.

Injection site: Lower abdomen, 2 inches lateral to the umbilicus, rotating sites daily to prevent lipodystrophy.

Cycle structure: 5 days on, 2 days off is a common practitioner pattern to reduce injection-site reactions and provide metabolic recovery periods, though no RCT has tested this cycling pattern specifically [8].

Expected outcome: Based on Phase II oral data showing 2.6 kg fat loss at 12 weeks with 1 mg oral dosing [4], subcutaneous practitioners targeting 300-500 mcg may see modest fat-mass reductions. Lean mass preservation during a deficit is anecdotal and not confirmed in any controlled human trial.

Evidence grade: Level II for fat-loss direction; Level V for MMA-specific application.

Phase 2: Post-Fight / Post-Camp Soft-Tissue Recovery (Weeks 1-12 post-fight)

Goal: Support ligamentous and cartilaginous tissue turnover following the high-impact stress of fight camp and competition.

Dose: 500 mcg subcutaneous injection, once daily, continuing on the same fasted-state protocol. Some practitioners increase to 500 mcg during acute recovery phases based on the ovine intra-articular cartilage study dose extrapolation [2], though this is a Level V practice.

Adjunct considerations: AOD-9604 is frequently co-administered with BPC-157 (body protection compound) in combat-sports peptide stacks. BPC-157 has its own separate animal-model evidence for tendon and ligament healing via upregulation of VEGF and growth factor receptor expression [9]. The two peptides are considered mechanistically complementary by practitioners, but no human RCT has tested the combination.

Duration: 8-12 weeks post-fight, followed by a minimum 4-week off-cycle before resuming.

Evidence grade: Level IV-V. The ovine cartilage data [2] and the chondrogenic stem-cell data [5] support biological plausibility, not clinical efficacy.

Phase 3: Off-Season Maintenance (Optional, Weeks 1-8)

Goal: Maintain favorable body composition between fight camps without the hormonal disruption of a full hGH or IGF-1 cycle.

Dose: 300 mcg subcutaneous injection, 5 days per week.

Rationale: Athletes who compete multiple times per year and need to manage weight-class eligibility without suppressing endogenous GH pulsatility may find AOD-9604 preferable to full hGH because IGF-1 neutrality has been documented in Phase II data [4]. This is a reasonable risk-harm reduction argument, not an efficacy claim.

Evidence grade: Level V (practitioner rationale, mechanistically supported).

Monitoring Labs and Safety Parameters

Safety monitoring for AOD-9604 should follow the same logic applied to any peptide that interacts with metabolic pathways, even when the interaction is expected to be mild. The FDA has reviewed an AOD-9604 GRAS (Generally Recognized as Safe) petition for oral food-additive status, a process that required submission of safety and pharmacokinetic data [10]. That dossier confirmed no clinically significant adverse events at doses up to 1 mg/day oral in 300 human subjects over 12 weeks [4].

Baseline Labs (Before Starting)

• Fasting glucose and insulin (to establish metabolic baseline and rule out pre-existing insulin resistance)
• IGF-1 (to confirm no pre-existing elevation and to monitor for any unexpected change)
• Complete metabolic panel (CMP), including liver function tests
• CBC with differential
• Lipid panel (AOD-9604 showed a non-significant trend toward reduced LDL in Phase II data)
• Thyroid function (TSH, free T4), as GH-axis peptides can interact with thyroid hormone metabolism [11]

8-Week Follow-Up Labs

Repeat fasting glucose, insulin, IGF-1, and CMP. Compare IGF-1 to baseline. A rise of more than 50 ng/mL above baseline warrants discontinuation and evaluation for a compound source that may contain full hGH contamination, since reputable AOD-9604 should not drive IGF-1 elevation [4].

Safety Signals to Monitor

Water retention is rare with AOD-9604 compared to full hGH because the fragment does not activate IGF-1 pathways that drive sodium retention [1]. Injection-site reactions (erythema, nodule formation) are the most commonly reported adverse effect in practitioner experience. Rotating injection sites and using 29-31 gauge insulin syringes reduces this risk.

Anti-Doping Considerations for Competitive Athletes

Combat sports athletes competing under organizations that adopt WADA rules (UFC, Bellator under USADA oversight, amateur boxing) must understand AOD-9604's regulatory position before use.

The 2024 WADA Prohibited List [12] prohibits under S2.2 "other growth factors and growth factor modulators," with specific language covering "any other agent with a similar chemical structure or similar biological effect." AOD-9604 is a structural fragment of hGH. A WADA-accredited laboratory detecting the peptide in urine or blood could argue it falls under S2 even without a name-specific listing.

No WADA-published analytical method for AOD-9604 detection in urine is currently in the public domain, but the absence of a published method does not mean one does not exist in WADA-accredited labs. Athletes subject to USADA or UKAD testing should consult a sports pharmacologist before use. The Global Drug Reference Online (GlobalDRO) database does not currently return a result for AOD-9604, which reflects absence of a name-specific entry, not a clearance for use [13].

Weight-Cut Timing and Detection Windows

The half-life of subcutaneous peptides in the AOD class is estimated at under 30 minutes based on GH fragment pharmacokinetic modeling [7]. Urinary detection windows for small peptides using mass spectrometry may extend beyond plasma half-life. No published detection-window study specific to AOD-9604 in humans exists at the time of this article.

Expected Timeline of Outcomes

The following timeline is constructed from Phase II human fat-loss data [4], the ovine cartilage study duration [2], and practitioner-reported experience. Readers should weight each entry by its evidence grade.

Weeks 1-2: Mild reduction in subcutaneous fat accumulation during caloric restriction, consistent with lipolytic mechanism. No subjective change in joint or soft-tissue comfort expected at this stage.

Weeks 3-6: Measurable fat-mass reduction on DEXA scan or skinfold assessment if caloric deficit is maintained. Some practitioners report reduced joint stiffness in this window, but this is Level V experience and may reflect concurrent training load reduction.

Weeks 6-12: Peak fat-loss response based on Phase II 12-week trial endpoint [4]. For soft-tissue recovery use cases, the ovine cartilage study ran 13 weeks to show histological improvement [2], suggesting any connective-tissue benefit, if present in humans, likely requires a full 8-12 week course.

After 12 weeks: A 4-week off period is standard practitioner practice before re-initiating. No human data on tachyphylaxis or receptor desensitization with AOD-9604 exist.

Sourcing, Compounding, and Quality Concerns

AOD-9604 sold to athletes exists entirely outside FDA-regulated pharmaceutical manufacturing. The FDA has not approved any AOD-9604 drug product for human use [10]. Compounding pharmacies in the United States cannot legally compound AOD-9604 for human use under current FDA compounding guidance, as it does not appear on the 503A or 503B bulk drug substance lists [14].

Athletes purchasing AOD-9604 are typically receiving research-chemical products. A 2018 analysis of peptide products sold online, published in Drug Testing and Analysis, found that 24 of 44 samples (54.5%) did not match their labeled content by mass spectrometry, and 8 samples contained no detectable active peptide [15]. Requesting a certificate of analysis from an ISO-accredited third-party laboratory before purchasing any peptide product is the minimum quality-assurance step a clinician should recommend.

Dr. Neil Resnick, writing in the Journal of Clinical Endocrinology and Metabolism, has noted that "the clinical evidence base for peptide fragments derived from growth hormone is insufficient to support routine therapeutic use outside of controlled trial settings" [11]. This position reflects the consensus of endocrinology societies, and clinicians working with athletes should document informed consent accordingly.

Practical Administration Guide

Reconstitution

AOD-9604 is typically supplied as a lyophilized powder in vials of 2-5 mg. Reconstitute with bacteriostatic water (not sterile water, which has no preservative and is single-use) at a ratio that yields a manageable injection volume. For a 2 mg vial, adding 2 mL bacteriostatic water gives 1 mg/mL (1,000 mcg/mL). A 300 mcg dose then requires 0.3 mL (30 units on an insulin syringe). Store reconstituted peptide refrigerated at 2-8°C and use within 28 days.

Injection Technique

Use a 29-31 gauge, 5/16-inch (8 mm) insulin syringe. Pinch a fold of skin at the injection site. Insert at a 45-degree angle for lower body fat percentages (typical in trained MMA athletes) or 90 degrees if subcutaneous fat layer is adequate. Inject slowly, withdraw, and apply gentle pressure. Do not rub the site, as this disrupts the subcutaneous depot.

Stack Timing When Using BPC-157 Concurrently

If co-administering BPC-157 for soft-tissue recovery (a common practitioner combination [9]), administer the two peptides in separate syringes at separate sites, separated by at least 15 minutes. No pharmacokinetic interaction data exist, and the separation is precautionary. AOD-9604 in the morning fasted state; BPC-157 at a separate time point, such as post-training or pre-sleep.